Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, announced that the first patients have been treated in the DAZZLE pivotal study of Kodiak’s anti-VEGF antibody biopolymer conjugate, KSI-301, in patients with treatment-naïve wet (neovascular) age-related macular degeneration (AMD).
“Treating the first patients in this pivotal study is an important step for Kodiak as we grow the company and accelerate our efforts with KSI-301,” said Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences. “On World Sight Day, we recognize that patients with wet AMD often need frequent eye injections of an anti-VEGF medication to preserve their vision. Next generation anti-VEGF biologics are thought to support half the patients on an every two-month interval and half the patients on an every three-month interval. Using our proprietary ABC Platform™, we designed KSI-301 from the outset as a therapy with extended durability. In our DAZZLE study, we are comparing the efficacy of KSI-301 on every three-, four-, or five-month dosing versus aflibercept on its every two-month interval. We believe our dosing regimen, with all patients on every three-month dosing or better, if successful, could position KSI-301 to be a leading anti-VEGF therapy for patients with wet AMD. Early data presented last month from our ongoing Phase 1b data of KSI-301 showed the majority of wet AMD patients treated with KSI-301 reached a four- or five-month interval without receiving retreatment.”
